A meta-analysis and systematic review: Adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Jiang, Shaojie ^a   Liu, Yingxia ^a   Wang, Linhai ^a   Duan, Chenyang ^b   Liu, Mengying ^b  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adjuvant treatment; Hepatocellular carcinoma; Interferon; Meta analysis; Viral hepatitis

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN;

ADJUVANT THERAPY; ANTIVIRAL THERAPY; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CHEMOEMBOLIZATION; DRUG EFFICACY; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; META ANALYSIS; MULTIPLE CYCLE TREATMENT; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SYSTEMATIC REVIEW; VIRUS HEPATITIS;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; HEPATITIS, VIRAL, HUMAN; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; PROGNOSIS;

EID: 84884495409     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-240     Document Type: Article

References (28)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterol 2007, 132(7):2557-2576.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362(9399):1907-1917. 10.1016/S0140-6736(03)14964-1, 14667750.
3. Paquet KJ, Koussouris P, Mercado MA, Kalk JF, Müting D, Rambach W. Limited hepatic resection for selected cirrhotic patients with hepatocellular or cholangiocellular carcinoma: a prospective study. Br J Surg 1991, 78(4):459-462. 10.1002/bjs.1800780423, 1851652.
4. Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999, 229(3):322-330. 10.1097/00000658-199903000-00004, 1191696, 10077043.
5. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005, 25(2):181-200. 10.1055/s-2005-871198, 15918147.
6. von Marschall Z, Scholz A, Cramer T, Schäfer G, Schirner M, Oberg K, Wiedenmann B, Höcker M, Rosewicz S. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003, 95(6):437-448. 10.1093/jnci/95.6.437, 12644537.
7. Wang L, Wu WZ, Sun HC, Wu XF, Qin LX, Liu YK, Liu KD, Tang ZY. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 2003, 7(5):587-594. 10.1016/S1091-255X(03)00072-6, 12850669.
8. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - a prospective randomized study of hepatitis C virus-related liver cancer. Hepatol 2000, 32(2):228-232.
9. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002, 89(4):418-422. 10.1046/j.0007-1323.2001.02054.x, 11952580.
10. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003, 138(4):299-306. 10.7326/0003-4819-138-4-200302180-00008, 12585827.
11. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, Liaw YF. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004, 100(2):376-382. 10.1002/cncr.20004, 14716774.
12. Piao CY, Fujioka S, Iwasaki Y, Fujio K, Kaneyoshi T, Araki Y, Hashimoto K, Senoh T, Terada R, Nishida T, Kobashi H, Sakaguchi K, Shiratori Y. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma - using an untreated, matched control cohort. Acta Med Okayama 2005, 59(5):217-224.
13. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM, . HCC Italian Task Force Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatol 2006, 44(6):1543-1554. HCC Italian Task Force.
14. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J, Zhou XD, Zhou J, Qiu SJ, Shen YF. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006, 132(7):458-465. 10.1007/s00432-006-0091-y, 16557381.
15. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, Fan ST, Wong J. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007, 245(6):831-842. 10.1097/01.sla.0000245829.00977.45, 1876947, 17522506.
16. Li M, Lu C, Cheng J, Zhang J, Cao C, Xu J, Xu J, Pan H, Zhong B, Tucker S, Wang D. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 2009, 24(8):1437-1444. 10.1111/j.1440-1746.2009.05863.x, 19486255.
17. Li N, Lai EC, Shi J, Guo WX, Xue J, Huang B, Lau WY, Wu MC, Cheng SQ. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol 2010, 17(1):179-185. 10.1245/s10434-009-0694-z, 19727956.
18. Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T, Kamimura T. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival. Hepatogastroenterology 2012, 59(114):529-532.
19. Marrero JATM. Current Treatment Approaches in HCC. Clin Adv Hematol Oncol 2013, 5(4):15-18.
20. Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H, Kawasaki T. Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005, 48(1):64-70. 10.1159/000082097, 15785092.
21. Chen RY, Bowden S, Desmond PV, Dean J, Locarnini SA. Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus. J Gastroenterol Hepatol 2003, 18(6):630-637. 10.1046/j.1440-1746.2003.03019.x, 12753143.
22. Li J, Liu K, Liu Y, Xu Y, Zhang F, Yang H, Liu J, Pan T, Chen J, Wu M, Zhou X, Yuan Z. Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity. Nat Immunol 2013, 14(8):793-803. 10.1038/ni.2647, 23832071.
23. Wang CJ, Xiao CW, You TG, Zheng YX, Gao W, Zhou ZQ, Chen J, Xue XB, Fan J, Zhang H. Interferon-alpha enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma. Mol Cancer 2012, 11(1):31. 10.1186/1476-4598-11-31, 3697897, 22569271.
24. Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatol 2000, 32(1):43-48.
25. Ji YJ, Li FF, Ren WH, Zhu YH, Qin CY. Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2013, 21(5):335-339.
26. Ormeci N. Short- and long-term effects of treatment of chronic hepatitis B and delta virus by IFN. Fundam Clin Pharmacol 2003, 17:651-658. 10.1046/j.1472-8206.2003.00194.x, 15015710.
27. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, Habu D, Tanaka T. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001, 3:196-197.
28. Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N, Hayashi J. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine 2006, 33:121-128. 10.1016/j.cyto.2005.08.011, 16522372.